polymyxin b

Polymyxin B Sulfate (Poly-RX) 是一个阳离子型表面活性剂抗生素剂，能够提高细胞膜的渗透性。

Polymyxin B 是一种多粘菌素抗生素，具有抗菌活性，通过与细菌壁的LPS高亲和力结合欸和增加细菌细胞膜的渗透性发挥作用，可用于研究耐药 （XDR） 革兰氏阴性菌 （GNB） 引起的感染。Polymyxin B 可用于研究内毒素血症。

Polymyxin B1-i is a polypeptide antibiotic.

Polymyxin B2 is an antibiotic primarily utilized for resistant Gram-negative infections. It is derived from the bacterium Bacillus polymyxa.

Polymyxin B nonapeptide TFA 是一种有用的有机化合物，可用于生命科学领域的相关研究，其产品编号为 T64687。

Polymyxin B2是一种抗生素，并且是从B. polymyxa分离出的阳离子脂肽抗生素polymyxin B的主要成分。该化合物对P. aeruginosa、A. baumannii、K. pneumoniae和E. cloacae菌株具有活性（MICs分别为1-2、0.5-1、0.25-0.5和0.25-1 µg/ml）。在体内实验中，以4 mg/kg剂量的Polymyxin B2能显著降低P. aeruginosa血液感染小鼠模型中的血液集落形成单位(CFUs)数量。

Polymyxin B nonapeptide acetate(86408-36-8 free base) 是一种阳离子环肽。 Polyxin B 九肽是 polyxin B 经酶解产生的衍生物。与 polyxin B 相比，polyxin B 九肽毒性低，缺乏杀菌活性，仍具有破坏革兰氏阴性菌外膜的能力。

Polymyxin B nonapeptide, a cationic cyclic peptide derived by enzymatic processing from the naturally occurring peptide polymyxin B, is able to increase the permeability of the outer membrane of Gram-negative bacteria toward hydrophobic antibiotics probab

Polymyxin B1, a potent antimicrobial lipopeptide derived from Bacillus polymyxa, has potential for treating multidrug-resistant Gram-negative bacterial infections.

Deacylpolymyxin B increases outer membrane permeability.

SPR741 acetate 是衍生自多粘菌素 B 的阳离子肽，通过增加革兰氏阴性细菌外膜的通透性来抑制严重的革兰氏阴性细菌感从而展现出对革兰氏阴性菌的抗菌活性。SPR741 acetate 常与抗生素联合使用来治疗一些疾病。

PA3552-IN-1 是一种抗生素佐剂， 可以降低 PA3552 的表达，恢复 MDR 铜绿假单胞菌 DK2 菌株对 Polymyxin B 的敏感性。

Antibacterial agent 247 (compound 30b) 作为一种高效的细菌 (bacterial) 拮抗剂，能够明显抑制铜绿假单胞菌生物膜的生成，其半抑制浓度（IC50）为5.8 μM，并针对多个毒力表型展现出抑制效果。此外，该化合物还能加强妥布霉素与多粘菌素B的联合治疗效果，提升其抗菌活性。

IKD-8344 is a macrocyclic dilactone originally isolated from an actinomycete species and has diverse biological activities, including anticancer, antimicrobial, and anthelmintic properties.1,2,3 It is cytotoxic to L5178Y murine leukemia cells (IC50 = 0.54 ng ml).1 IKD-8344 inhibits growth of the mycelial form of C. albicans (MIC = 6.25 μg ml) and potentiates the activity of polymyxin B against the multidrug-resistant pathogenic bacterium B. cenocepacia.2,3 It is active against T. spiralis in vitro and in vivo.1 |1. Minami, Y., Yoshida, K., Azuma, R., et al. Structure of a novel macrodiolide antibiotic IKD-8344. Tetrahedron Lett. 33(48), 7373-7376 (1992).|2. Hwang, E.I., Yun, B.S., Yeo, W.H., et al. Compound IKD-8344, a selective growth inhibitor against the mycelial form of Candida albicans, isolated from Streptomyces sp. A6792. J. Microbiol. Biotechnol. 15(4), 909-912 (2005).|3. Loutet, S.A., El-Halfawy, O.M., Jassem, A.N., et al. Identification of synergists that potentiate the action of polymyxin B against Burkholderia cenocepacia. Int. J. Antimicrob. Agents 46(4), 376-380 (2015).

Polymyxin E1，是一种肽类抗生素，也是原初从B. polymyxa分离得到的阳离子脂肽抗生素colistin的主要成分。对P. aeruginosa和E. coli具有活性（MICs分别为2和0.8 µg ml）。

Polymyxin E2 是一种肽类抗生素，也是最初从B. polymyxa分离出的阳离子脂肽抗生素colistin的主要成分。该化合物对植物致病菌X. oryzae具有活性（EC50 = 0.21 µg/ml），并且在温室研究中，当以200 µg/ml的浓度应用时，能够预防和逆转水稻细菌性叶枯病。

6-Methylheptanoic acid (6-methyl-heptanoic acid) 具有口服毒性，参与合成多粘菌素B和粘菌素半抗原PMB-A。

SPR741 TFA (NAB741 TFA) is a cationic peptide derived from polymyxin B and is a potentiator molecule.

SPR741, formerly NAB741 (12), is a cationic peptide derived from polymyxin B and is one such potentiator molecule that is under development for the treatment of serious Gram-negative bacterial infections.